Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Infographics

2018 was a big year for industry news. Here's what might happen next in artificial intelligence, the 2020 presidential election, pharma, and more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Some of our 2018 predictions on consolidation, pharma, and investment came true, while others were less predictable.

Principal, Oliver Wyman

Physicians are best positioned to curtail the $265 billion wasted annually on unneeded care.

Global Head, Health Services, Oliver Wyman
Professor of Surgery and Health Policy, Johns Hopkins Medicine
Engagement Manager, Oliver Wyman

Seeing a return on investment in pharma marketing means understanding what happens to every dollar.

Engagement Manager, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Digital & Analytics, Oliver Wyman

Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting

Insights in your inbox

Subscribe

Our new advice for the Blues, who are in a formative period as market trends create both sizable risk and sizable opportunity.

Principal, Oliver Wyman Actuarial Consulting
Global Head, Health Services, Oliver Wyman
Principal, Oliver Wyman

In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Health & Life Sciences, Oliver Wyman

2018 has already seen transformational industry news. Here we dig deeper and analyze what the industry can expect in M&A, investments, pharma and much more.

Partner, Health & Life Sciences, Oliver Wyman
Managing Partner, Health & Life Sciences, Oliver Wyman

Some of our 2017 healthcare predictions on value-based care, consumers, mergers, startups, and pharma came true, while others were less predictable.

Principal, Oliver Wyman

As one of the fastest-rising categories of healthcare costs, pharmaceuticals need to develop a metric that explains pricing.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe